Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA

  Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual
  Healthcare Conference in San Francisco, CA

JPMorgan Healthcare Conference 2014

Business Wire

COPENHAGEN, Denmark -- January 14, 2014

Symphogen A/S, a private biopharmaceutical company with leadership in
recombinant antibody mixtures for therapeutic use, today presented its
achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual
Healthcare Conference in San Francisco, California. The presentation was made
by Kirsten Drejer, CEO.

Pipeline update

Symphogen has continued to expand its oncology pipeline to include projects
that simultaneously address targets on cancer cells along with targets in the
tumor microenvironment.

Sym004

Symphogen’s lead oncology product, Sym004, which was out-licensed to Merck
KGaA in 2012, continues to produce new data. At ASCO in June 2013, study
results in patients with metastatic Colorectal Cancer (mCRC) and Squamous Cell
Carcinoma of the Head and Neck Cancer (SCCHN) were presented. The program is
advancing towards investigational new drug applications across a variety of
indications.

Pan-HER

Symphogen is accelerating its development plans for pan-HER and expects to
file an IND in 2015.

Corporate update

Symphogen’s Board was further strengthened in December 2013 by the appointment
of Annika Espander Jansson as a non-executive Director of the Company. Annika
brings strong financial acumen from her experience both as a sell-side analyst
in the healthcare sector and as an investor.

Symphogen remains strongly financed. During 2013, the Company completed a €141
equity financing from top-tier investors and has a current cash position of
€100 million.

During the first half of 2014, Symphogen will relocate to a new domicile in
Denmark where manufacturing facilities will enable the Company to produce
antibodies for early clinical development.

Kirsten Drejer, Ph.D., Symphogen’s Chief Executive Officer, commented: “In
2013 Symphogen advanced its pipeline of novel antibody therapeutics for the
treatment of cancer. Our investors continued to support Symphogen’s strategy
to become a leading European oncology-focused biotech company and we look
forward to expanding our capabilities in our new up-to-date facilities.”

About Symphogen A/S

Symphogen is developing next-generation antibody therapeutics for the
treatment of cancer and is dedicated to bringing truly innovative oncology
products to the market.

The Company has advanced the frontier of antibody discovery by creating
well-characterized antibody mixtures that address multiple oncology targets in
a single drug product. The Company has matured its oncology pipeline and has
currently brought two product candidates into the clinic. The Company’s
productive technology suite - capable of identifying, selecting and
manufacturing optimal antibody mixtures – fuels Symphogen’s innovative
pipeline.

The lead oncology product, Sym004, was out-licensed to Merck KGaA in 2012
following phase 2 clinical data in late stage cancer patients.

In total, the Company has raised €249 million in equity capital from premier
international investors including Novo, Essex Woodlands Health Ventures and
PKA, and employs 100 people, most of whom are based at Symphogen’s facilities
in Copenhagen.

Contact:

Symphogen A/S
Kirsten Drejer, + 45 22 10 99 59
Chief Executive Officer
kd@symphogen.com
Martin Olin, + 45 40 21 85 32
Chief Financial Officer
mol@symphogen.com
or
Annes Associates
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Consilium Strategic Communications
Mary-Jane Elliott or Amber Bielecka, +44 207 920 2354
symphogen@consilium-comms.com
 
Press spacebar to pause and continue. Press esc to stop.